First Tracks Biotherapeutics is trading at $37.35, up +20.64%, after announcing positive top-line results from Cohort 1 of its Phase 1b trial of ANB033 in celiac disease today.
- The study of ANB033 in a gluten-challenge cohort showed statistically significant benefits in reducing intestinal damage and symptoms compared to placebo.
- ANB033 achieved a +0.49 placebo-adjusted difference in villus height-to-crypt depth ratio (p=0.009) and demonstrated a favorable safety profile with no serious adverse events.